BIRC5 and breast carcinoma: At the clinical level, retrospective Kaplan–Meier analysis of expression cohorts of breast tumor showed that high survivin (BIRC5) expression levels significantly (p-value < 0.0001) correlate with poor relapse-free survival (HR = 1.98) in endocrine therapy-treated ER+ breast cancer patients (Figure 4C).